ADRX

ADARx Pharmaceuticals Inc

14.20

Nov 13 • 3:59 PM ET -0.71 (-4.76%)

13.99

Aftermarket • 5:00 PM ET -0.21 (-1.48%)

Healthcare Biotechnology USA Small NASD

Nov 12, 6:45 PMADARx reports fiscal Q3 2026 non-GAAP EPS of -$1.74 and revenue of $746,000, missing estimates

Peers: ARWR ALNY IONS WVE ABUS DYN STOK SLN VKTX RNA

| Held by: VTI VXF TMED VTWO TDNA VTWG TSEE VTWV

Scroll to Statements

Index	-
Market Cap	1.57B
Enterprise Value	679.31M
Income	-
Sales	-
Book/sh	5.36
Cash/sh	8.13
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	-
IPO	Sep 25, 2026

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	2.65
P/C	1.75
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	21.08
Current Ratio	21.08
Debt/Eq	0.01
LT Debt/Eq	0.01
Option/Short	No / Yes

EPS (ttm)	-
EPS next Y	-
EPS next Q	-0.36
EPS this Y	-
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	- -
Sales past 3/5Y	- -
EPS Y/Y TTM	-
Sales Y/Y TTM	-
EPS Q/Q	-88.80%
Sales Q/Q	-
Earnings	Nov 12 AMC
EPS/Sales Surpr.	-111.76% -14.14%

Insider Own	59.08%
Insider Trans	8.56%
Inst Own	4.83%
Inst Trans	15.66%
ROA	-
ROE	-
ROIC	-
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-11.14%
SMA50	-17.10%
SMA200	-17.10%
Trades

Shs Outstand	107.26M
Shs Float	45.36M
Short Float	3.97%
Short Ratio	2.77
Short Interest	1.80M
52W High	23.21 -38.82%
52W Low	12.50 13.60%
Volatility	12.11% 9.40%
ATR (14)	1.67
RSI (14)	37.08
Beta	-
Rel Volume	0.90
Avg Volume	651.37K
Volume	587,964

Perf Week	7.33%
Perf Month	-19.77%
Perf Quarter	-
Perf Half Y	-
Perf YTD	-35.75%
Perf Year	-
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Recom	1.00
Target Price	34.25
Prev Close	14.91
Price	14.20
Change %	-4.76%

Consensus

Strong Buy

Avg. Price Target

$34.25

Implied Upside

+141.2%

Analysts4incl. previous ratings

Rating Distribution4 Buy · 0 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Oct 20, 2026	Initiated	UUBS	Buy	$35	+146.5%
Oct 20, 2026	Initiated	TTD Cowen	Buy
Oct 20, 2026	Initiated	MMorgan Stanley	Overweight	$32	+125.4%
Oct 20, 2026	Initiated	JJP Morgan	Overweight	$38	+167.6%

Nov-12-26 04:05PM	ADARx Reports Third Quarter 2026 Financial Results and Provides Business Updates (GlobeNewswire) +12.11%
Nov-09-26 08:00AM	ADARx Pharmaceuticals to Present at the UBS Global Biopharma Conference (GlobeNewswire)
Oct-01-26 04:15PM	ADARx Pharmaceuticals Announces the Closing of Full Exercise of Underwriters' Option to Purchase Additional Shares Granted in Its Initial Public Offering (GlobeNewswire) -6.60%

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Chimovits Erez	Director	Sep 28 '26	Buy	17.00	61,516	1,045,772	9,292,025	Sep 30 05:29 PM
GORDON CARL L	Director	Sep 28 '26	Buy	17.00	950,000	16,150,000	14,325,529	Sep 30 05:25 PM
ORBIMED ADVISORS LLC	Director	Sep 28 '26	Buy	17.00	950,000	16,150,000	14,325,529	Sep 30 05:23 PM
SR ONE CAPITAL MANAGEMENT, LLC	10% Owner	Sep 28 '26	Buy	17.00	1,600,000	27,200,000	5,554,094	Sep 29 09:45 PM
George Simeon	Director	Sep 28 '26	Buy	17.00	1,600,000	27,200,000	5,554,094	Sep 29 09:43 PM

ADARx Pharmaceuticals, Inc. is a late-clinical-stage biotechnology company. It focuses on developing next-generation small interfering RNA (siRNA) therapeutics for diseases with significant unmet medical needs. The company was founded by Zhen Li in December 2019 and is headquartered in San Diego, CA.

Co-FounderDr. Li Zhen Ph.D.

Chief Scientific OfficerDr. A. Robert MacLeod Ph.D.

CFO & Chief Business OfficerMr. Ryan Fisk M.B.A.

Ph.D.Dr. Christopher Claeboe M.B.A.

Chief Technology OfficerDr. Rui Zhu Ph.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

All the Features.Half the Price.

ADRX

ADARx Pharmaceuticals Inc

Upgrade your Finviz experience

All the Features.
Half the Price.